Jeremiah Ostriker, who plumbed dark forces that shape universe, dies at 87
'Ostriker was arguably the most important single figure in convincing the astronomical community that this natural and seductive assumption is wrong,' David Spergel, the president of the Simons Foundation, which supports scientific research, wrote in 2022, nominating Dr. Ostriker, his mentor, for the Crafoord Prize, the astronomical equivalent of a Nobel. He cited Dr. Ostriker's 'eloquent advocacy for the then-radical new model in which the visible stars in galaxies were only a minor pollutant at the center of a much larger halo of dark matter of unknown composition.'
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
Dr. Ostriker's work, he said, was 'the grandest revision in our understanding of galaxies' in half a century.
Advertisement
Jerry Ostriker, as he was known to friends and colleagues, had a prickly sense of humor and a soft but commanding voice. Willing to go wherever the data and scientific calculations led him, the astrophysicist was not shy about questioning assumptions — or having fun. Prominently displayed in his home was a youthful photo, taken in Cambridge, Mass., of himself in suit and tie driving a motor scooter as his wife, Alicia, seated behind him, lifted a bottle of wine to her lips. (A close look shows the cork still in the bottle.)
Advertisement
'He had the quickest wit of any scientist I have encountered,' said James Peebles, a Nobel physics laureate and a colleague of Dr. Ostriker's at Princeton. 'And I don't remember ever matching him in a spontaneous debate' on any issue.
Asked in a 1988 oral history interview for the American Institute of Physics if he had favored any of the models of the universe being batted about in the 1970s, when he entered the field — whether the universe was finite or infinite, whether it had a beginning or was somehow always here, whether it would expand forever or crash back down in a big crunch — he said he had not.
'Scientists have followed their own biases, and my principle bias at the time was being contemptuous and intolerant of all of these people who had specific models,' he answered. 'How could they be so certain when the evidence was as confusing and inconclusive?'
Jeremiah Paul Ostriker was born April 13, 1937, on the Upper West Side, the second of four siblings. His father, Martin Ostriker, ran a clothing company, and his mother, Jeanne (Sumpf) Ostriker, was a teacher. Babe Ruth lived around the corner, and the children used to chase his car for autographs.
'I must have been the classic nerd child,' Dr. Ostriker wrote in a memoir published in the Annual Review of Astronomy and Astrophysics in 2016. He first became interested in science when he was 4: His mother started reading science books aloud to get him to sit still for an oil portrait, and the readings stuck.
Advertisement
Jerry Ostriker went to Harvard University, where he planned to study chemistry. Instead, he switched to physics, which appealed to what he called his 'cosmic perspective.'
Dr. Ostriker, in an image provided by Rebecca Ostriker, in Harvard Square in 1983.
REBECCA OSTRIKER/NYT
'I probably spent more time on literature than I spent on science,' he said in the oral history interview.
He soon began commuting to Brandeis University to visit Alicia Suskin, who was an aspiring artist and poet. They were married in 1958, while they were still undergraduates.
Alicia Ostriker, a professor emerita of English at Rutgers University, became an award-winning poet and has often written her husband into her work. In turn, he found poetry in astrophysics. 'As an astrophysicist, you get a perspective on humankind,' he said, describing it as 'sweating on this little grain of spinning sand.'
Dr. Ostriker, at his family's summer home in Chester, Mass., in 1987. His wife, Alicia, is in the background.
REBECCA OSTRIKER/NYT
In addition to his wife and his daughter Rebecca, an editor for the opinion section of The Boston Globe, Dr. Ostriker leaves two other children, Eve Ostriker, an astrophysicist at Princeton, and Gabriel Ostriker, a data engineer; a sister, Naomi Seligman; two brothers, Jon and David; and three grandchildren.
After graduating from Harvard in 1959, Dr. Ostriker worked at the Naval Research Laboratory for a year before enrolling in graduate school at the University of Chicago, splitting his time between the university's Yerkes Observatory and the physics department, where he worked under the future Nobel laureate Subrahmanyan Chandrasekhar.
He earned his doctorate in 1964. After a postdoctoral year at the University of Cambridge, where he rubbed elbows with future black hole eminences Stephen Hawking and Martin Rees, Dr. Ostriker joined Princeton as a research scientist. He remained there for 47 years, rising through the ranks to become chair of the astronomy department and provost of the university.
Advertisement
Dr. Ostriker wrote a series of papers that would lead astronomy to the dark side.
He wondered whether galaxies, like stars, could break apart if they rotated too fast. The question was particularly relevant to so-called disc galaxies like the Milky Way, which are shaped sort of like a fried egg, with a fat, yolky center surrounded by a thin, white flat of stars.
Working with Peebles, he constructed a computer simulation and found that disc galaxies were indeed unstable. They would fall apart unless there was something we couldn't see, a halo of some additional invisible mass, lending gravitational support.
Whatever this stuff called dark matter was — dim stars, black holes, rocks, exotic subatomic particles left over from the Big Bang — there could be a lot of it, as much as 10 times the mass of ordinary atomic matter.
It was one of the first theoretical arguments that there must be more to galaxies than could be seen in starlight. In the 1930s, astronomer Fritz Zwicky had suggested that most of the mass in galaxies was 'dark.' His idea was largely ignored until Dr. Ostriker and Peebles published their paper in 1973.
The reaction from the scientific community was predominantly hostile, Dr. Ostriker said. 'I couldn't see particularly why,' he said in the oral history. 'It was just a fact.'
A year later, incorporating more data from galaxy clusters and other star systems, he and his colleagues argued that, in fact, most of the mass in the universe was invisible.
Advertisement
By the early 1980s, the idea of dark matter had become an accepted part of cosmology, but there remained conundrums, including calculations that suggested stars were older than the universe in which they lived.
The missing ingredient, Dr. Ostriker and theoretical physicist Paul Steinhardt, then at the University of Pennsylvania, suggested in 1995, was a fudge factor known as the cosmological constant. Einstein had come up with this concept in 1917 but had later abandoned it, considering it a blunder.
As Steinhardt recalled, he and Dr. Ostriker were 'convinced that a universe with only dark and ordinary matter could not explain the existing observations.' But once they added the cosmological constant, everything came out right.
They were not the only ones with this idea. Cosmologists Michael Turner, now retired from the University of Chicago, and Lawrence Krauss, now retired from Arizona State University, also argued in favor of bringing back the constant. 'To say Jerry was a giant in the field is an understatement,' Turner wrote in an email, adding, 'Sparring with Jerry over science was a privilege and often a learning experience.'
Three years later, two competing teams of astronomers discovered that the expansion of the universe was being accelerated by a 'dark energy' acting as the cosmological constant, pushing galaxies apart. The cosmological constant then became part of a standard model of the universe, as Dr. Ostriker and others had predicted.
Dr. Ostriker worked at Princeton for almost a half century, becoming chair of the astronomy department and provost of the university.
DENISE APPLEWHITE/PRINCETON UNIVERSITY/NYT
In another series of papers, he and various collaborators transformed astronomers' view of what was going on in the space between stars.
Dr. Ostriker and Renyue Cen, also of Princeton, concluded in 1999 that most ordinary atomic matter in the nearby universe was invisible, taking the form of intergalactic gas heated to millions of degrees by shock waves and explosions.
Advertisement
At Princeton, Dr. Ostriker helped set up the Sloan Digital Sky Survey, a collaboration aimed at remapping the entire sky in digital form with a dedicated telescope at Apache Point Observatory in Sunspot, N.M.
'The survey is going to increase our knowledge and our understanding of the universe a hundredfold,' he told The New York Times in 1991. 'The map is not going to show us how the universe began, but it will show us the nature and origin of large-scale structure, the most interesting problem in astrophysics today. With an answer to this problem, we will be able to better approach the question of how it all began.'
The survey, started in 1998, is now in its fifth iteration and has generated some 10,000 research papers and archived measurements of a half-billion stars and galaxies, all free to any astronomer in the world.
As provost, Dr. Ostriker led the effort to vastly expand the university's financial aid program, changing many loans to grants that would not need to be repaid, making a Princeton education more egalitarian.
In 2000, he was awarded the National Medal of Science by President Clinton.
Dr. Ostriker retired from Princeton in 2012, just as his daughter Eve was joining the astronomy faculty there. He took a part-time position at Columbia University, returning to his childhood neighborhood.
'Growing up in New York City, I couldn't see the stars,' he once told the Times.
He found them anyway, and a whole lot more that we can't see with or without the glare of streetlights.
It was a passion that never waned. Encountered recently by a reporter on the sidewalk in front of Columbia, Dr. Ostriker launched into an enthusiastic description of a promising new theory of dark matter.
Early in 2023, by then ailing, he took to his bed at home. But he kept up with his research by email and had regular pizza lunches with colleagues.
Apprised recently of results from the James Webb Space Telescope that seemed to reinforce his ideas about dark matter, he wrote in an email to his colleagues, 'Keep up the good work.'
The dark universe he helped conjure half a century ago has developed a few small cracks, leading to new ideas about the nature of that dark matter.
'It's a very, very, very specific and clear theory. So therefore, God bless it, it can be wrong,' Dr. Ostriker said in a recent interview. 'That's the way science proceeds. And what we know about it is that it is a little bit wrong, not a lot wrong.'
Rees, a cosmologist at the University of Cambridge and the Astronomer Royal, summed up Dr. Ostriker's life this way: 'Some scientists come up with pioneering ideas on novel themes; others write definitive 'last words' on already-established topics. Jerry was in the first category.'
'He wrote among the earliest papers — now classics — on the nature of pulsars, the evidence for dark matter and on galaxy formation and cosmology. His flow of papers continued into his 80s,' Rees added. 'He enthusiastically engaged in new data and in computational techniques. He inspired younger colleagues and collaborators, not just at Princeton but around the world.'
This article originally appeared in
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Geek Wire
a day ago
- Geek Wire
UW researchers discover AI-powered breakthrough that could boost precision cancer treatment
The co-lead authors of a study publishing today in Science describing AI-designed proteins for target health theraphies, from left: Julia Bonzanini, Nathan Greenwood and Bingxu Liu. All are researchers with UW Medicine's Institute for Protein Design. (IPD Photo) A breakthrough in the science used to customize the treatment of cancer and other diseases is so promising that researchers at the University of Washington are planning to launch a company to commercialize the technology. The strategy uses artificial intelligence to create proteins that recognize and bind to specific markers on diseased cells, creating what are essentially biological neon signs that attract immune cells to destroy the targets. The research comes from the lab of Nobel laureate David Baker and UW Medicine's Institute for Protein Design, which Baker leads, and is being published today in the journal Science. Additional study authors come from multiple UW departments, the Garcia Lab at Stanford University, and the Scheinberg Lab at Memorial Sloan Kettering Cancer Center. 'Detecting unhealthy cells is one of the main jobs of the immune system, but it doesn't always notice the subtle signs of cancer or viral infection,' Baker said in a statement. 'In this study, we show that computer-designed proteins can help human immune cells spot the right targets and function more effectively.' The work could lead to significant advancements in precision immunotherapy, which delivers disease-fighting drugs that are crafted for individual patients. The key to this personalized approach lies in understanding how cells display their identity on their surfaces. The outside membrane of a cell is studded with molecules that include small proteins called peptides that reveal a cell's inner workings, including if it's cancerous or infected by a virus such as HIV. The scientists used RFdiffusion and ProteinMPNN — AI-tools built by the Institute for Protein Design — to efficiently and cheaply engineer proteins that recognize the unique peptides. University of Washington biochemist and Nobel Prize laureate David Baker at his office in Seattle. (GeekWire Photo / Lisa Stiffler) The custom-made proteins can then be integrated into chimeric antigen receptors (CARs), which are engineered molecules that attract and activate immune-system warriors called T cells to attack specific targets. In their study, the researchers designed proteins for 11 peptide targets and eight successfully triggered a T-cell response. Of those eight, two produced such a strong immune response that the T cells killed the targeted cells. The peptide targets included HIV fragments and tumor-related protein mutations. 'We've shown how advances in protein design could make personalized cancer therapy possible, and we intend to start a company to turn these results into real therapies that benefit patients,' said Bingxu Liu, co-lead author of the study and postdoctoral scholar in the Baker Lab. Since 2014, the Institute for Protein Design has spun off 10 startups, and Baker has co-founded 21 tech companies. When Baker won the Nobel Prize in October, the Royal Swedish Academy of Sciences noted that 'his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors.' The researchers involved in the latest study explained that the strategy can be easily adapted to new scenarios. Within days, the team was able to take one of its successful proteins and use AI to modify it to target new cancer and virus-associated peptides. The process could make it much cheaper to create personalized treatments. 'I'm hopeful that this will lead to new therapies that are more accessible to patients around the world who do not benefit from current state-of-the-art cancer treatments,' said Julia Bonzanini, a co-lead author and Baker Lab graduate student. Researchers worldwide can access online the open-source software used in the research. Other authors of the Science paper, titled 'Design of high-specificity binders for peptide–MHC-I complexes,' are Nathan Greenwood, Amir Motmaen, Jeremy Meyerberg, Tao Dao, Xinyu Xiang, Russell Ault, Jazmin Sharp, Chunyu Wang, Gian Marco Visani, Dionne Vafeados, Nicole Roullier, Armita Nourmohammad, David Scheinberg and Christopher Garcia. RELATED:


Forbes
a day ago
- Forbes
Chan Zuckerberg Initiative Introduces New GREmLN Model For Genetics
3D illustration of a DNA molecule with sparkling effects symbolizing complexity and genetic ... More diversity. Futuristic concept of genomics, precision medicine, and computational life sciences. If you've been paying attention to modern research and AI, you know that genetics is a major application of this technology to our lives. Alphafold, for which its founders received a Nobel prize in science, is a major example, but it's just the tip of the iceberg when it comes to what AI is doing in healthcare, and in genetics in particular. This month we have a new announcement from the Chan Zuckerberg Initiative backed by Mark Zuckerberg and Melissa Chan that contemplates a brand new system called GREmLN (Gene Regulatory Embedding-based Large Neural model) for identifying cellular behavior. It may help with cancer research and work on other diseases. Part of the project involves an imaging technique, and assistance in developing software for scientists. There's also what CZ calls a 'single cell data set' of 1 billion cells, developed with 10X Genomics and Ultima Genomics. From reading documentation, it sounds like what this means is that teams assembled data on no less than a billion cells, in order to build a collective model of what an average cell would look like and how it would function. The new model, scientists suggest, can help to characterize genetic drivers of disease, and find new ways to restore diseased cells to health. Four Major Goals and Challenges Amongst the announcement of this ground-breaking resource, spokespersons at CZ identify four broader objectives scientists are reaching for: One involves building an AI-based virtual cell model – which GREmLN is presumably instrumental in. Another is 'developing novel imaging technology to map, measure and model complex systems,' which sounds like a similar type of exercise. Reportedly, the teams also hope to figure out how to directly sense inflammation in the body, and to harness the human immune system for various kinds of immunotherapy. Parsing these objectives further, you can see how the new GREmLN model will drive research on what the CZ Institute calls 'molecular logic' or the study of how parts of a cell interact or work together. What are Biohubs? A press release from Chan Zuckerberg also mentions the creation of Biohubs as laboratories fueling collaborative development, or, in the words of spokespersons, 'cross-disciplinary research institutions.' ChatGPT provides a definition of a Biohub, and points out that the Chan Zuckerberg Biohubs are not the same as a series of Biohubs developed by the World Health Organization. 'Biohubs are collaborative research centers designed to accelerate breakthroughs in biomedical science by fostering interdisciplinary cooperation, sharing resources, and facilitating innovation,' the model notes. 'Typically established through partnerships between universities, research institutions, healthcare providers, government agencies, and industry leaders, Biohubs aim to address complex biological and medical challenges by combining expertise across biology, medicine, engineering, computing, and data science. … Prominent examples include the Chan Zuckerberg Biohub, which unites Stanford, UCSF, and UC Berkeley researchers to tackle infectious diseases and advance biomedical knowledge through open science.' Of the WHO Biohubs: 'A totally separate WHO initiative aimed at sharing biological materials (like virus samples with pandemic potential) among member states… So, while (CZ Biohubs and WHO Biohubs) share the 'Biohub' name, their missions, governance, and affiliations are entirely distinct.' The concept, however, is the same – scientists are banding together to do more innovative work on cell structure, for example, in nucleus and mitochondria DNA. A little research shows some of the distinctions between different types of DNA present in a cell. A lot of the DNA is isolated in the nucleus of the cell, but there's also mitochondria, less attached to that central cluster. Literature Weighs In Fans of Madeleine L'Engle's youth fiction in the 1980s will note that her work explored the idea of subcellular entities and their impact on macroscopic systems. Just for fun. I ask ChatGPT about L'Engle's impact on modern cellular and genomic research. 'Madeleine L'Engle's work didn't explicitly prefigure specific contemporary research into genetics or mitochondria, but her writing, particularly A Wrinkle in Time (1962), A Wind in the Door (1973), and the rest of her Time Quintet, did anticipate broad scientific and philosophical themes related to cellular biology, mitochondrial function, interconnectedness, and universal harmony,' the model said. 'In A Wind in the Door, for instance, L'Engle explores the concept of 'farandolae,' fictional microscopic entities within mitochondria, whose harmony or disharmony directly affects the health of living organisms and even the universe. Her vision captured a holistic view of biology, recognizing mitochondria as fundamental life engines, long before mainstream science widely emphasized mitochondria's central role in health, aging, and diseases.' How many readers remember the farandolae, which L'Engle characterized in promoting a kind of social symbiosis that was a more prominent idea in a less data-driven age? 'The young farandolae cannot fill an adult role, so they maintain a parasitic existence on the adult farae,' writes a poster on Literature Stack Exchange, where human readers get together to ruminate on different aspects of a text. 'In fact, so long as they are under the influence of the Echthroi, they revel in their parasitism. It is all taking and no giving…' In any case, ChatGPT provides this summary: 'Though not predictive in a literal scientific sense, L'Engle's imaginative storytelling prefigured ideas in modern genetics and mitochondrial research—particularly notions of cellular symbiosis, bioenergetics, systemic interconnectedness, and the vital relationship between microscopic structures and macrocosmic health.' Driving Further Change It's easy to see how these partnerships will allow scientists to work more proactively on disease solutions. I thought this news was worth covering as we move through a banner year for artificial intelligence in healthcare. We are finding use cases everywhere, from diagnosis, to scheduling, to the kinds of research that support these clinical solutions. That's a feather in AI's cap. However, we just might still have a place for the philosophical, sometimes fictional portrayal of such systems, as in L'Engle's work that leans more into the speculative than the technical approach. What do you think?
Yahoo
4 days ago
- Yahoo
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer
Updated efficacy data will be presented from the REZILIENT1 trial of zipalertinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who were previously treated with amivantamab Preliminary findings to be shared from the cohort of patients with uncommon non-ex20ins EGFR mutations enrolled in the REZILIENT2 trial of zipalertinib PRINCETON, N.J. and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced the presentation of new data from zipalertinib REZILIENT1 and REZILIENT2 trials at the International Association of the Study of Lung Cancer's (IASLC) 2025 World Conference on Lung Cancer (WCLC), to be held September 6-9, 2025, in Barcelona, Spain. The abstracts accepted for mini oral presentations include updated efficacy and safety data from the Phase 2b REZILIENT1 trial, focusing on patients with EGFR ex20ins NSCLC previously treated with amivantamab, as well as the preliminary efficacy and safety results from the Phase 2 parallel cohort REZILIENT2 trial in patients with advanced or metastatic NSCLC harboring uncommon non-ex20ins EGFR mutations. "Previously, zipalertinib has demonstrated clinical activity against ex20ins and preclinical activity against uncommon, non-ex20ins EGFR-mutant NSCLC," said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology. "We look forward to sharing updated data from the REZILIENT1 and REZILIENT2 trials at the upcoming 2025 World Conference on Lung Cancer, suggesting the potential for zipalertinib to make a meaningful difference in the lives of patients with certain types of NSCLC." "Despite advances in the treatment landscape, there remains significant unmet need for NSCLC patients with EGFR exon 20 insertion mutations and for those with uncommon non-ex20ins EGFR mutations," said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. "Taken together, the updated results from REZILIENT1 and new data from the REZILIENT2 study highlight the potential of zipalertinib to play an important role in the evolving treatment landscape for patients with NSCLC harboring less common EGFR mutations." Session titles and information for the two abstracts are listed below. Full abstract details will be available via the conference website at 1 p.m. EDT August 13, 2025. Title: Zipalertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab Session Name: MA08 - Common and Uncommon EGFR Mutations, New Treatments in the HorizonSession Type: Mini Oral PresentationSession Date: Tuesday, September 9, 2025Session Time: 11:30 a.m. – 12:45 p.m. CESTPresenter: Zofia Piotrowska, MD Title: Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR MutationsSession Name: MA08 - Common and Uncommon EGFR Mutations, New Treatments in the Horizon Session Type: Mini Oral PresentationSession Date: Tuesday, September 9, 2025Session Time: 11:30 a.m. – 12:45 p.m. CESTPresenter: Hibiki Udagawa, MD, PhD About ZipalertinibZipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib has received Breakthrough Therapy Designation from the FDA. Zipalertinib is investigational and has not been approved by any health authority. Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S. About Taiho Oncology, mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small-molecule clinical candidates targeting solid-tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Baar, Switzerland and Oakville, Ontario, Canada. For more information, visit and follow us on LinkedIn and X. Taiho Oncology and the Taiho Oncology logo are registered trademarks of Otsuka Holdings Co., Ltd. or its subsidiaries. About Cullinan TherapeuticsCullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan's portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at and follow us on LinkedIn and X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company's beliefs and expectations regarding our plans regarding future data presentations, the clinical development and regulatory filing plan and timeline of zipalertinib, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, and other statements that are not historical facts. The words "believe," "continue," "could," "estimate," "expect," "intends," "may," "plan," "potential," "project," "pursue," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any NDA or other regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. Contacts Taiho OncologyLeigh Labrie+1 609.664.9878 LLabrie@ Cullinan TherapeuticsInvestorsNick Smith+1 401.241.3516nsmith@ Media Rose Weldon +1 215.801.7644 rweldon@ View original content to download multimedia: SOURCE Taiho Oncology Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data